Insider Selling: Progyny, Inc. (NASDAQ:PGNY) Director Sells 5,000 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) Director Norman Payson sold 5,000 shares of the business’s stock in a transaction on Tuesday, December 29th. The shares were sold at an average price of $41.85, for a total transaction of $209,250.00. Following the transaction, the director now owns 528,446 shares of the company’s stock, valued at $22,115,465.10. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Norman Payson also recently made the following trade(s):

  • On Tuesday, December 22nd, Norman Payson sold 5,000 shares of Progyny stock. The shares were sold at an average price of $40.64, for a total transaction of $203,200.00.
  • On Wednesday, December 16th, Norman Payson sold 5,000 shares of Progyny stock. The shares were sold at an average price of $40.67, for a total transaction of $203,350.00.
  • On Wednesday, December 9th, Norman Payson sold 5,500 shares of Progyny stock. The shares were sold at an average price of $37.23, for a total transaction of $204,765.00.
  • On Wednesday, December 2nd, Norman Payson sold 5,500 shares of Progyny stock. The shares were sold at an average price of $36.27, for a total transaction of $199,485.00.
  • On Monday, November 23rd, Norman Payson sold 16,500 shares of Progyny stock. The shares were sold at an average price of $31.43, for a total transaction of $518,595.00.
  • On Monday, November 9th, Norman Payson sold 16,500 shares of Progyny stock. The shares were sold at an average price of $29.26, for a total transaction of $482,790.00.
  • On Wednesday, November 4th, Norman Payson sold 16,500 shares of Progyny stock. The shares were sold at an average price of $26.71, for a total transaction of $440,715.00.
  • On Wednesday, October 28th, Norman Payson sold 16,500 shares of Progyny stock. The stock was sold at an average price of $25.13, for a total transaction of $414,645.00.
  • On Wednesday, October 21st, Norman Payson sold 16,500 shares of Progyny stock. The stock was sold at an average price of $27.17, for a total transaction of $448,305.00.
  • On Wednesday, October 14th, Norman Payson sold 16,500 shares of Progyny stock. The stock was sold at an average price of $29.04, for a total transaction of $479,160.00.

Progyny stock opened at $42.39 on Friday. The company has a market capitalization of $3.67 billion and a PE ratio of -36.86. The firm has a fifty day simple moving average of $36.44 and a two-hundred day simple moving average of $29.40. Progyny, Inc. has a twelve month low of $15.59 and a twelve month high of $44.22.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. The business had revenue of $98.93 million during the quarter, compared to the consensus estimate of $92.54 million. Progyny had a negative net margin of 3.81% and a positive return on equity of 10.04%. The firm’s revenue for the quarter was up 61.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.03 earnings per share. As a group, analysts predict that Progyny, Inc. will post 0.12 earnings per share for the current year.

Several research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Progyny from a “sell” rating to a “hold” rating and set a $31.00 target price for the company in a research report on Saturday, October 24th. ValuEngine lowered shares of Progyny from a “buy” rating to a “hold” rating in a research report on Wednesday, September 9th. Bank of America upped their target price on shares of Progyny from $30.00 to $35.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 25th. BidaskClub upgraded shares of Progyny from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 25th. Finally, SVB Leerink boosted their price target on shares of Progyny from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, November 6th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $35.14.

Several large investors have recently modified their holdings of PGNY. Vanguard Group Inc. raised its stake in shares of Progyny by 132.7% during the second quarter. Vanguard Group Inc. now owns 2,520,042 shares of the company’s stock valued at $65,041,000 after acquiring an additional 1,437,114 shares during the last quarter. Teacher Retirement System of Texas bought a new position in shares of Progyny during the third quarter valued at about $30,930,000. FMR LLC raised its stake in shares of Progyny by 163.3% during the second quarter. FMR LLC now owns 1,093,386 shares of the company’s stock valued at $28,220,000 after acquiring an additional 678,054 shares during the last quarter. BlackRock Inc. raised its stake in shares of Progyny by 29.2% during the third quarter. BlackRock Inc. now owns 2,000,997 shares of the company’s stock valued at $58,889,000 after acquiring an additional 451,831 shares during the last quarter. Finally, Rothschild & Co. Asset Management US Inc. bought a new position in shares of Progyny during the third quarter valued at about $11,063,000. 54.09% of the stock is owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Article: What is the Shanghai Stock Exchange Composite Index?

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.